Info:

KLINISCHE STUDIEN

 

NEUE:

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women PDF

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial PDF

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine PDF

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection PDF

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions PDF

- - - - - - - - - -

Villa L.L. et al., British Journal of Cancer (2006) 95, 1459-1466, High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of followup. PDF

Garland S.M. et al., The New England Journal of Medicine 2007;356:1928-43, Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases (FUTURE I). PDF

The FUTURE II Study Group, The New England Journal of Medicine 2007;356:1915-1927, Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions (FUTURE II). PDF

Joura E.A. et al., The Lancet 2007;369:1693-702, Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. PDF

The FUTURE II Study Group, The Journal of Infectious Diseases 2007;196:1438-46, Prophylactic of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection. PDF

SPEZIELLE KLINISCHE DATEN

Prophylaxe:
Barr E. et al., Vaccine 26(2008) 1-14, Prophylactic HPV vaccines: New interventions for cancer control. PDF

Gedächtniszellen:
Olsson S.E. et al., Vaccine 25 (2007) 4931-4939, Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. PDF

SCREENING / IMPFUNG

Bosch F.X. et al., British Journal of Cancer (2008) 98, 15-21, HPV and cervical cancer: screening or vaccination? PDF

MÄDCHEN UND KNABEN

Reisinger K.S. et al., The Pediatric Infectious Disease Journal 207;26:201-209, Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents. PDF

GENITALWARZEN FRAUEN

Krüger Kjaer S. et al., The Journal of Infectious Diseases 2007;196:1447-54, The Burden of Genital Warts: A Study of Nearly 70,000 Women from the General Female Population in the 4 Nordic Countries. PDF

KOSTENEFFIZIENZDATEN

Szucs T.D. et al., Current Medical Research and Opinion 2008;24 (5):1473-1483, Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. PDF

BAG-UNTERLAGEN

Bundesamt für Gesundheit, Eidgenössische Kommission für Impffragen, Fact-Sheet: Gebärmutterhalskrebs und andere HPV-bedingte Gesundheitsschäden. PDF

Bundesamt für Gesundheit, Eidgenössische Kommission für Impffragen, Arbeitsgruppe HPV-Impfung, Richtlinien und Empfehlungen: Empfehlungen zur Impfung gegen humane Papillomaviren (HPV), Februar 2008. PDF

 

Weiter Information finden Sie unter: